VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG) Files An 8-K Entry into a Material Definitive Agreement
ITEM 1.01ENTRY INTO MATERIAL DEFINITIVE AGREEMENTS

Stem Cell Lab Development Agreement

On July 6, 2017, the Company’s wholly-owned subsidiary Halo Cell Sciences, Ltd, (“Halo”) formed and organized under the laws of Grand Cayman, executed a revised Stem Cell Lab Development Agreement (“Revised Agreement”) with DaVinci Centre for Wellness and Alternative Therapies, Ltd (“DaVinci”) to which DaVinci will provide the clinical facilities and staff support necessary for the Company to begin offering stem cell therapies in the Caymen Islands. Halo and DaVinci previously executed a Development Agreement as was described in the Company’s Current Report on Form 8-K dated March 23, 2017 and filed with the Securities and Exchange Commission on March 29, 2017. The initial Development Agreement never became effective due to the failure of a planned financing, which was a condition to such effectiveness. The Revised Agreement will also not become effective until and unless a $1.5 million financing is fully funded.

A copy of the Revised Development Agreement is filed herewith as Exhibit 10.1

ITEM 9.01:EXHIBITS

VITRO DIAGNOSTICS INC Exhibit
EX-10.1 2 vitro_10ez1.htm REVISED AGREEMENT STEM CELL LAB DEVELOPMENT AGREEMENT    This STEM CELL LAB DEVELOPMENT AGREEMENT (this “Agreement”) made the 6th day of July,…
To view the full exhibit click here

About VITRO DIAGNOSTICS, INC. (OTCMKTS:VODG)

Vitro Diagnostics, Inc., doing business as Vitro Biopharma, is engaged in the development, manufacturing and distribution of stem cell products and related tools for use in research, drug discovery and clinical trials. The Company’s clinical products include clinical grade MSC-Gro for mesenchymal stem cell (MSC) expansion prior to transplantation; an equine MSC cell line with application to treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, and others; testing and therapies related to endogenous stem cell activation; diagnostic testing of stem cell activation and determination of stem cell functional status, and cell-based assays for discovery of stem cell activation agents and new drugs for the treatment of osteoporosis. The Company offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells.